Renal Oncocytoma Overview

Save information for later
Sign Up

Learn About Renal Oncocytoma

What is the definition of Renal Oncocytoma?
Renal oncocytoma is a benign (noncancerous) growth of the kidney. Renal oncocytoma generally do not cause any signs or symptoms and are often discovered incidentally (by chance) while a person is undergoing diagnostic imaging for other conditions. Some people with Renal oncocytoma will have abdominal or flank pain; blood in the urine; and/or an abdominal mass. Although these tumors can occur in people of all ages, they most commonly develop in men who are over age 50. The exact underlying cause of most isolated (single tumor affecting one kidney) Renal oncocytomas is unknown. Multiple and bilateral (affecting both kidneys) Renal oncocytomas sometimes occur in people with certain genetic syndromes such as tuberous sclerosis complex and Birt-Hogg-Dube syndrome.
What are the alternative names for Renal Oncocytoma?
  • Renal oncocytoma
  • Oncocytoma kidney
  • Oncocytoma renal
Who are the top Renal Oncocytoma Local Doctors?
Elite in Renal Oncocytoma
Dr. Alexander Kutikov
Urology
Elite in Renal Oncocytoma
Dr. Alexander Kutikov
Urology

Temple Faculty Practice Plan Inc

3509 N Broad St, 
Philadelphia, PA 
215-707-2111
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alexander Kutikov is an Urologist in Philadelphia, Pennsylvania. Dr. Kutikov is rated as an Elite provider by MediFind in the treatment of Renal Oncocytoma. His top areas of expertise are Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Bladder Cancer, Nephrectomy, and Cystectomy.

Elite in Renal Oncocytoma
Dr. Ian S. Ganly
Otolaryngology
Elite in Renal Oncocytoma
Dr. Ian S. Ganly
Otolaryngology

Mskcc Surgery Group

1133 York Ave, 
New York, NY 
646-888-7100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ian Ganly is an Otolaryngologist in New York, New York. Dr. Ganly is rated as an Elite provider by MediFind in the treatment of Renal Oncocytoma. His top areas of expertise are Thyroid Cancer, Papillary Thyroid Cancer, Tongue Cancer, Thyroidectomy, and Laryngectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Michael A. Gorin
Elite in Renal Oncocytoma
Dr. Michael A. Gorin
Urology
Elite in Renal Oncocytoma
Dr. Michael A. Gorin
Urology

UPMC Western Maryland

12234 Williams Rd, 
Cumberland, MD 
301-724-0132
Languages Spoken:
English
See accepted insurances

Michael Gorin is an Urologist in Cumberland, MD. Dr. Gorin is rated as an Elite provider by MediFind in the treatment of Renal Oncocytoma. His top areas of expertise are Renal Oncocytoma, Prostate Cancer, Renal Cell Carcinoma (RCC), Nephrectomy, and Prostatectomy.

View All Doctors
What are the latest Renal Oncocytoma Clinical Trials?
A Prospective Diagnostic Cohort Study to Compare the Accuracy of Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT for Patients With Clinically Localized Renal Tumors
A Prospective Diagnostic Cohort Study to Compare the Accuracy of Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT for Patients With Clinically Localized Renal Tumors
Enrollment Status: Recruiting
Publish Date: March 19, 2025

Summary: The goal of this clinical trial is to better tell apart whether kidney tumors are benign (not cancer) or malignant (cancer) based on a biopsy or imaging tests and ask patients how they feel about decisions they make about treatment of their kidney tumor. The main objectives are: To estimate and compare the diagnostic accuracy of renal mass biopsy alone, PEER (with renal mass biopsy), and 99mTc-ses...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Renal Cancer Detection With Liquid Biopsy
Renal Cancer Detection With Liquid Biopsy
Enrollment Status: Recruiting
Publish Date: January 30, 2024
Intervention Type: Diagnostic test

Summary: Glycosaminoglycans (GAGs) were significantly altered in localized as well advanced RCC compared to healthy samples. In addition, GAG scores correlated with progression-free survival and overall survival (OS) in a prospective cohort of patients with metastatic ccRCC and localized RCC. However, it is still unknown whether alterations in plasma and urine GAGs are exquisitely specific to RCC or are sh...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center